碧桂園(02007.HK)擬獲郵儲銀行(01658.HK)500億人幣意向性授信額度
據內地媒體獲悉,碧桂園(02007.HK)於昨日(24日)與中國郵政儲蓄銀行(01658.HK)(601658.SH)簽約,建立長期戰略合作關係。
通過此次簽約,郵儲銀行將為碧桂園提供不超過500億元人民幣意向性授信額度,授信範圍包括但不限於房地產開發貸款、併購貸款、按揭業務、保函、保理、債券投資以及其它形式的資金融通等。
據悉,今日及明日(25日)還會有多家銀行與碧桂園簽約,給予信貸支持。
人民銀行日前召開全國性商業銀行信貸工作座談會,人行並將面向六家商業銀行推出2,000億元人民幣「保交樓」貸款支持計劃,為商業銀行提供零成本資金,以鼓勵其支持「保交樓」工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.